Fig. 5: PDGFR-α/β inhbition reverses to chemotherapy resistance in vivo. | Oncogenesis

Fig. 5: PDGFR-α/β inhbition reverses to chemotherapy resistance in vivo.

From: RETRACTED ARTICLE: Platelet-derived growth factor receptor-α and -β promote cancer stem cell phenotypes in sarcomas

Fig. 5

a Tumor growth curves for HT1080 xenografts treated with doxorubicin (Dox) 4 mg/kg), imatinib (90 mg/kg), PDGFR-α shRNA and PDGFR-β shRNA (sh.PDGFR-α/β), and/or DMSO. There were five mice per group. b Representative immunofluorescence images of treated HT1080 tumors and stained for PCNA (purple), cleaved caspase-3 (red), and CD133 (green). White scale bars 25 μm; yellow scale bar 50 μm. c,d Graphs displaying the number of cleaved caspase 3(+), CD133(+), and dual cleaved caspase 3(+)/CD133(+) cells on immunofluorescence imaging analysis. Bars represent standard deviation. *p < 0.05 compared to control and monotherapy groups

Back to article page